Back to Search
Start Over
Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial
- Source :
- International Journal of Rheumatic Diseases. 15:188-196
- Publication Year :
- 2011
- Publisher :
- Wiley, 2011.
-
Abstract
- Aim: Rheumatoid arthritis (RA) is an important rheumatologic disease in Asia-Pacific countries, as in other parts of the world. However, limited information is available regarding RA therapy in this region. The Asia-Pacific Study in Patients to be Treated With Etanercept or an Alternative Listed DMARD (APPEAL) compared efficacy and safety of etanercept (ETN) + methotrexate (MTX) versus usual disease-modifying anti-rheumatic drugs (DMARDs) + MTX (reflecting regional practice) in subjects with moderate to severe RA from multiple Asia-Pacific countries. Method: In this open-label, active-comparator, parallel-design, multicenter study, subjects (n = 300) in the Asia-Pacific region were randomized to ETN + MTX (n = 197) or DMARD + MTX (n = 103). The primary efficacy endpoint was the American College of Rheumatology (ACR) response (ACR-N) area under the curve (AUC) over 16 weeks. Results: Baseline characteristics were similar between groups. At Week 16, ACR-N AUC indicated a significantly greater response with ETN + MTX compared with DMARD + MTX (mean difference –145.3; P
- Subjects :
- musculoskeletal diseases
medicine.medical_specialty
education.field_of_study
business.industry
Population
Area under the curve
Arthritis
medicine.disease
Rheumatology
Surgery
law.invention
Etanercept
Pharmacotherapy
Randomized controlled trial
immune system diseases
law
Rheumatoid arthritis
Internal medicine
medicine
skin and connective tissue diseases
education
business
medicine.drug
Subjects
Details
- ISSN :
- 17561841
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- International Journal of Rheumatic Diseases
- Accession number :
- edsair.doi...........011608a91d4f78af5b008ed94625c0d2